EMA Application withdrawn: Vynfinit — Endocyte Europe, B.V.

View source ↗

Summary

The EMA withdrew the application for Vynfinit (Endocyte Europe, B.V.) for ovarian neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Vynfinit

Snippet

Status: Application withdrawn. Therapeutic area: Ovarian Neoplasms. MAH: Endocyte Europe, B.V.. Decision date: 21/03/2014